KRAS and colorectal carcinoma: This approach enabled them to identify pathways such as nicotinamide adenine dinucleotide kinase (NADK) and fructose metabolism (ketohexokinase, KHK), which are specifically active in KRAS-mutated CRC, representing potential drug targets.